Clinical Trials
24 trialsNCT05393999 2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2 Withdrawn
NCT05209308 2023-03-16
CORAL
MEI Pharma, Inc.
Phase 2 Withdrawn
NCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT00003407 2023-02-02
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Rush University Medical Center
Phase 2 Withdrawn
NCT00003405 2021-10-14
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
Phase 2 Withdrawn
NCT00004878 2020-07-31
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01479582 2018-12-21
Providing Access to Cord Blood Units for Transplants
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00006091 2018-11-14
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01162031 2018-05-21
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Stanford University
Phase 2 Withdrawn
NCT02420938 2016-12-06
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00446173 2015-08-25
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00004040 2015-08-19
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
Hoag Memorial Hospital Presbyterian
Phase 2 Withdrawn
NCT00833534 2015-03-06
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT00939328 2015-03-06
S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00081055 2014-12-04
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
Mesoblast, Ltd.
Phase 2 Withdrawn
NCT02028039 2014-01-06
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00601991 2013-04-02
A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT01649622 2012-11-08
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00006090 2012-10-10
Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00301912 2012-10-02
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT00960726 2012-07-30
NOV-002 in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00343447 2012-05-03
Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT01131247 2011-07-20
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Nevada Cancer Institute
Phase 2 Withdrawn
NCT00485966 2008-11-05
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Cylene Pharmaceuticals
Phase 2 Withdrawn